Overview of the epidemiology of malignancy in immune deficiency

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 4 SUPPL., 1999, Pages

  Mueller, Nancy ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cancer; Immunity; Viruses

Indexed keywords

AIDS RELATED COMPLEX; CANCER INCIDENCE; CANCER RISK; CONFERENCE PAPER; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN CANCER; VIRUS TRANSMISSION; WART VIRUS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, AIDS-RELATED; ORGAN TRANSPLANTATION; PAPILLOMAVIRIDAE; SARCOMA, KAPOSI; SKIN NEOPLASMS;

CANCER VIRUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0033178409     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Hepatitis Viruses, vol. 59. Lyon: IARC, 1994.
2. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses, vol. 64. Lyon: IARC, 1995.
3. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Immunodeficiency Viruses and Human T-cell Lymphotropic Viruses, vol. 67. Lyon: IARC, 1996.
4. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8, vol. 70. Lyon: IARC, 1997.
5. Hollinger FB. Hepatitis B virus. In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields Virology, 3rd ed, vol. 2. Philadelphia: Lippincott-Raven Publishers, 1995:2739-807.
6. Ishihara S, Okayama A, Stuver S, et al. Association of HTLV-I antibody profile of asymptomatic carriers with proviral DNA levels of peripheral blood mononuclear cells. J Acquir Immune Defic Syndr 1994;7:199-203.
7. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields Virology, 3rd ed, vol. 2. Philadelphia: Lippincott-Raven Publishers, 1995:2397-446.
8. Filopovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: genetic risk factors for lymphomas. Cancer Res 1992;52(Suppl):5465s-7s.
9. Rosen FS, Cooper MD, Wedwood RJP. The primary immunodeficiencies. N Engl J Med 1995;333:431-0.
10. Ott G, Ott MM, Müller-Hermelink HK. EBV DNA in nodal and extranodal non-Hodgkin's lymphomas: impact of cell lineage, morphology, and site of origin. Toxicol Lett 1993;67:341-51.
11. Teramoto N, Sarker AB, Tonoyama Y, et al. Epstein-Barr virus infection in the neoplastic and nonneoplastic cells of lymphoid malignancies. Cancer 1996;77:2339-47.
12. d'Amore F, Johansen P, Houmand A, Weisenburger DD, Mortensen LS. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood 1996;87:1045-55.
13. List AF, Gerco FA, Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 1987;5:1673-89.
14. Riddler SA, Breinig MC, McKnight JLC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-84.
15. Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
16. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996;61:715-21.
17. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995;60:183-9.
18. Goedert JJ, Coté TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998;351:1833-9.
19. Selik RM, Rabkin CS. Cancer death rates associated with human immunodeficiency virus infection in the United States. J Natl Cancer Inst 1998;90:1300-2.
20. Holmberg SD, Buchbinder SP, Conley LJ, et al. The spectrum of medical conditions and symptoms before acquired immunodeficiency syndrome in homosexual and bisexual men infected with the human immunodeficiency virus. Am J Epidemiol 1995;141: 395-504.
21. Mueller N, Hinkula J, Wahren B. Elevated antibody titers against cytomegalovirus among patients with testicular cancer. Int J Cancer 1988;41:399-403.
22. Algood CB, Newell GR, Johnson DE. Viral etiology of testicular tumors. J Urol 1988;139:308-10.
23. Heinzer H, Dieckmann K-P, Huland E. Virus-related serology and in situ hybridization for the detection of virus DNA among patients with testicular cancer. Eur Urol 1993;24:271-6.